The most biologically active metabolite 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) has well known direct effects on osteoblast growth and differentiation in vitro. 
Introduction
Vitamin D deficiency, a common condition in the elderly population, has been associated to numerous skeletal health problems. Vitamin D deficiency causes a decrease of calcium absorption from the intestines and secondary hyperparathyroidism which leads to bone loss, osteoporosis and mineralization defects in the long term [1] . Vitamin D status is determined by the measurement of the metabolite 25-hydroxyvitamin D 3 (25(OH)D 3 ) [2] , which is the major circulating form of vitamin D. The metabolite 25(OH)D 3 is metabolized in the kidney by the enzyme 1a-hydroxylase (CYP27B1) into the biologically most active metabolite 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) [3] , which is the classical pathway for vitamin D activation. Both 25(OH)D 3 and 1,25(OH) 2 D 3 are metabolized by the enzyme 24-hydroxylase (CYP24), responsible for the first step in the inactivation process, to respectively 24R,25-dihydroxyvitamin D 3 (24R,25(OH) 2 D 3 ) and 1,24R,25-trihydroxyvitamin D 3 (1,24R,25(OH) 3 D 3 ) [4] . In addition, alternative pathways for vitamin D activation have been described, and one of such is the CYP11A1-mediated pathway [5] . This pathway for activation of vitamin D has been demonstrated in placentas ex utero, adrenal glands ex vivo and in cultured epidermal keratinocytes and colonic Caco-2 cells [6, 7] . Hydroxyvitamin D derivatives synthesized by the action of CYP11A1 not only act on the vitamin D receptor (VDR), but also on the retinoic acid related receptors a and c (RORa and RORc) [8] .
The metabolite 1,25(OH) 2 D 3 exerts its function by binding to the VDR which is present in numerous tissues, including bone tissue [3] . Bone formation is affected by 1,25(OH) 2 D 3 both in an indirect and direct manner. Indirect effects of 1,25(OH) 2 D 3 occur through stimulation of intestinal calcium absorption required for the maintenance of normal serum calcium levels and bone mineralization [3] . Direct effects of 1,25(OH) 2 D 3 on osteoblasts have been demonstrated in vitro. These in vitro studies show that 1,25(OH) 2 D 3 decreases osteoblast proliferation and stimulates osteoblast differentiation by increasing collagen type I synthesis and by secreting several non-collagenous proteins, for example osteocalcin and osteopontin [9] . The metabolite 1,25(OH) 2 D 3 also increases the alkaline phosphatase (ALP) activity and the mineralization of bone matrix synthesized by human osteoblasts [10] [11] [12] .
While the effects of 1,25(OH) 2 D 3 on human osteoblasts are well-known, fewer studies have focused on the response of human osteoblasts to the precursor 25(OH)D 3 . Van Driel et al [12] have shown that 25(OH)D 3 increases the ALP activity, the osteocalcin expression, and the early phase of mineralization in the human SV-HFO cell line. In primary osteoblasts, 25(OH)D 3 inhibits the proliferation, stimulates the expression of osteocalcin and osteopontin, and increases the mineralization [13] . The actions of 25(OH)D 3 on human osteoblasts are thought to take place after its conversion to 1,25(OH) 2 [12] [13] [14] . Locally synthesized 1,25(OH) 2 D 3 is thought to act in an autocrine or paracrine manner to regulate osteoblast proliferation and differentiation [12, 13] . However, it is largely unknown whether, in addition to the effects of 25(OH)D 3 that occur via hydroxylation to 1,25(OH) 2 D 3 , 25(OH)D 3 can affect primary osteoblast function on its own.
In addition to 1a-hydroxylase, osteoblasts express 24-hydroxylase [12, 13] [15] . In addition, CYP24 knockout mice demonstrate a delayed fracture healing [16] . In vitro, 24R,25(OH) 2 D 3 has positive actions on SV-HFO osteoblast differentiation by increasing ALP activity, osteocalcin secretion and matrix mineralization [17] . These findings suggest that primary human osteoblasts not only respond to the active metabolite 1,25(OH) 2 
Materials and Methods

Primary human osteoblast culture
Primary human osteoblasts were isolated from redundant trabecular bone fragments obtained from healthy donors undergoing pre-implant bony reconstruction of the mandible or maxilla with autologous bone from the anterior iliac crest. The donor group consisted of 11 males and 12 females with a mean age of 49.3618.6 years. The protocol was approved by the Medical Ethical Review Board of the VU University Medical Center, Amsterdam, the Netherlands, and all donors gave their written informed consent.
A modification of the methods of Beresford and Marie [18, 19] was used. Shortly, the trabecular bone fragments were minced into small pieces and washed extensively with phosphate buffered saline (PBS). The bone pieces were treated with 2 mg/ml collagenase type II (300 U/mg; Worthington Biochemical Corporation, Lakewood, NJ, USA) for two hours in a shaking waterbath at 37uC. The pieces were placed in culture flasks with Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12; GIBCO, Life technologies) supplemented with 10% Fetal Clone I (HyClone, Thermo Fisher Scientific), 100 U/ ml penicillin and 100 mg/ml streptomycin (GIBCO, Life technologies), 1.25 mg/ml fungizone (GIBCO, Life technologies) and incubated at 37uC and 5% CO 2 . Medium was changed twice a week until cells reached confluence. To enable differentiation, primary human osteoblasts were cultured in osteogenic medium. Osteogenic medium consisted of complete medium with 10 mmol/L b-glycerophosphate (SigmaAldrich), 10 nmol/L dexamethasone (Sigma-Aldrich) and 50 mg/ ml ascorbic acid (Sigma-Aldrich).
Primary human osteoblast treatments
All experiments were performed in complete medium with 5% Fetal Clone I unless otherwise stated and all conditions, including treated and control groups, contained 0.1% ethanol.
Proliferation
Primary human osteoblasts of the first passage were plated out in a 96 wells plate at a density of 4.000 cells/well. After 24 hours cells were exposed to medium with 25 
Differentiation
Primary human osteoblasts of the first or second passage were seeded into a 12 wells plate at a cell density of 40.000 cells/well. Cells were allowed to attach to the well for 24 hours before medium was changed to osteogenic medium with 25(OH)D 3 (0 or 400 nmol/L) or 1,25(OH) 2 D 3 (0 or 100 nmol/L). Medium was replaced every 3 or 4 days by complete medium with or without 25(OH)D 3 or 1,25(OH) 2 D 3 . Culture medium was collected at day 3, 7, 10 and 14 of the differentiation culture and cell lysates were prepared for the measurement of osteoblast markers.
Procollagen type I aminoterminal propeptide (P1NP) was measured in culture medium using the UniQ PINP radioimmunoassay (Orion Diagnostica). The interassay variation was ,8% over the whole concentration range.
ALP activity was measured in cell lysate that was made by scraping the cells in PBS-0.1% triton [12] , and by sonificating of the lysate two times for 30 seconds at 50 Hz. ALP activity was measured by the ALP IFCC liquid assay (Roche Diagnostics), performed on a Modular analyzer (Roche Diagnostics). ALP activity was adjusted for total protein, measured by the BCA protein assay (Thermo Fisher Scientific) according to the manufacturer's protocol.
Osteocalcin was measured in culture medium using an enzyme immunoassay (Biosource). Interassay variation was 15% at a level of 0.5 nmol/L, 8% at a level of 2 nmol/L and 9% at a level of 8 nmol/L.
RNA isolation and real time RT-PCR
For RNA experiments primary human osteblasts of the first or second passage were seeded into a 12 wells plate at a cell density of 40.000 cells/well. Medium was changed after 24 hours and primary human osteoblasts were treated with different vitamin D metabolites as indicated in the figure legends. Total RNA isolation of primary osteoblasts was performed using the RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. For removing residual DNA amounts an additional on-column DNA treatment was accomplished during the RNA isolation procedure. Total RNA concentration was measured with the Nanodrop spectrophotometer (Nanodrop Technologies).
RNA was reverse transcribed from 100 ng total RNA in a 20 ml
1 mmol/L Betaïne, 10 ng/ml random primer, 0.4 U/ml RNAsin (Promega) and 5 U/ml M-MLV RT-enzym (Promega). The PCR reaction of total 25 ml contained 3 ml cDNA, 300 nmol/L reverse and forward primer (table 1) and SYBR Green Supermix (BioRad). The PCR was performed on an iCycler iQ Real-Time PCR Detection System (Bio-Rad): 3 minutes at 95uC, 40 cycli consisting of 15 seconds at 95uC and 1 minute at 60uC. The relative gene expression was calculated by the 2 2DCt method and TATA binding protein (TBP) was used as housekeeping gene.
siRNA transfection
Silencing RNA was carried out to suppress CYP27B1 mRNA. Knockdown was performed using CYP27B1 SMART pool and the negative control ON-TARGET plus SMART pool (Thermo Fisher Scientific). Primary human osteoblasts of the first passage were electroporated with the Microporator Pipetype Electroporation System (Digital Bio, Hopkinton, MA, USA) using 1 pulse of 1200 V for 40 ms. After electroporation, 100.000 cells were seeded in a 24 wells plate in DMEM/F12 with 10% fetal clone I. Two days after electroporation of the cells, total RNA was isolated to determine CYP27B1 knockdown. Four days after the electroporation treatment, cells were incubated in complete medium with 25(OH)D 3 (0 or 400 nmol/L) for 3 days. Complete medium was collected and stored at 220uC until 1,25(OH) 2 
measurements
Primary human osteoblasts were seeded into a 6 wells plate with a cell density of 500.000 cells/well. High bone cell density was used to raise the 1,25(OH) 2 D 3 concentrations above the detection levels. After 24 hours, cells were incubated in medium consisting of DMEM/F12, 0.2% BSA, 100 U/ml penicillin, 100 mg/ml streptomycin, 1.25 mg/ml fungizone and 25(OH)D 3 (0, 100, 200, 400 or 1.000 nmol/L). Medium was collected after 24 hours exposure of osteoblasts to 25(OH)D 3 .
The metabolite 1,25(OH) 2 D 3 was measured in non-conditioned and conditioned medium using a radioimmunoassay (IDS). Cross reactivity with 25(OH)D 3 and 24R,25(OH) 2 D 3 was 0.1% and , 0.01% respectively. Intra-assay variation was 8% at a level of 25 pmol/L and 9% at a level of 70 pmol/L, and interassay variation was 11% at a concentration of 25 and 70 pmol/L.
The metabolites 25(OH)D 3 and 24R,25(OH) 2 D 3 were analyzed in non-conditioned and conditioned medium using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Briefly, samples were incubated with deuterated internal vitamin D standards (d6-25(OH)D 3 and d6-24R,25(OH) 2 D 3 ) and protein-precipitated using acetonitrile. Supernatant was, after PTAD derivatization, purified using a Symbiosis online solid phase extraction (SPE) system (Spark Holland, Emmen, the Netherlands), followed by detection with a Quattro Premier XE tandem mass spectrometer (Waters Corp., Milford, MA). Intra-assay variation of 25(OH)D 3 was 9.6%, 6.0% and 8.5% at a level of 58, 191 and 516 nmol/L, respectively. Intra-assay variation of 
Statistical analyses
Data were presented as mean 6 SEM. Differences between 2 groups were assessed using Wilcoxon signed rank test. Differences between 3 or more groups were assessed using Friedman test followed by Dunn's post hoc test. A p-value,0.05 was considered to be significant (*p,0.05, **p,0.01, ***p,0.001). 
Results
Effects
on mRNA levels of genes involved in primary human osteoblast differentiation. ALP mRNA levels (Fig. 3A) 3 were strongly reduced to respectively 16%, 20%, 29% and 33% of non-conditioned values (Fig. 5A) (Fig. 5C ) was also produced in a dose-dependent manner after 25(OH)D 3 treatment. 
Effects of 25(OH)D 3 on mRNA levels of genes involved in primary human osteoblast differentiation after CYP27B1 silencing
Silencing of CYP27B1 gene expression was used to examine whether 25(OH)D 3 can directly act on osteoblast function. Treatment with CYP27B1 siRNA resulted in a 58% reduction of CYP27B1 mRNA compared to the control culture (p,0.05) (Fig. 6A) . After 25(OH)D 3 treatment, the reduction of CYP27B1 mRNA resulted in a decreased 1,25(OH) 2 D 3 synthesis of 30% (p, 0.05) compared to the control culture (Fig. 6B) . Levels of 24R,25(OH) 2 D 3 ( Fig. 6C ) and 25(OH)D 3 ( Fig. 6D) did not change in silenced and control cultures. After 72 hours of 25(OH)D 3 treatment, the reduction of CYP27B1 mRNA was still 62% in the absence of 25(OH)D 3 and 45% in the presence of 25(OH)D 3 (Fig. 6E) . No significant differences were seen between mRNA levels of CYP24 (Fig. 6F) , VDR (Fig. 6G) , ALP (Fig. 6 H) , osteocalcin ( Fig. 6I) and osteopontin (Fig. 6J ) in control and CYP27B1-silenced cells that were exposed to 25(OH)D 3 .
Effects of 24R,25(OH) 2 D 3 on osteoblast differentiation
In addition to 1,25(OH) 2 D 3 , we showed that osteoblasts are able to synthesize 24R,25(OH) 2 D 3 from the precursor 25(OH)D 3 . To examine whether 24R,25(OH) 2 D 3 can act on osteoblast differentiation, primary human osteoblasts were cultured in the presence (Fig. 7B) , osteocalcin (6182%; p,0.01) (Fig. 7C ) and osteopontin (387%; p,0.05) (Fig. 7D ) mRNA levels.
Effects of 24R,25(OH) 2 D 3 on VDR, CYP27B1 and CYP24 mRNA levels in primary human osteoblasts
We did not observe effects of 24R,25(OH) 2 D 3 on mRNA levels of VDR (Fig. 8A) and CYP27B1 (Fig. 8B) . The metabolite 24R,25(OH) 2 D 3 highly induced CYP24 mRNA (Fig. 8C) reduced osteoblast proliferation and stimulated the differentiation as shown by increasing ALP activity (mRNA and protein) and osteocalcin secretion (mRNA and protein). Our study confirms previous studies in human osteoblastic cell lines and primary osteoblasts [12, 13, 20] .
The effects of 25(OH)D 3 on proliferation and differentiation likely occur through hydroxylation to 1,25(OH) 2 D 3 [12, 13] , since we and others demonstrated that osteoblasts are able to synthesize the active metabolite 1,25(OH) 2 D 3 after exposure to the precursor 25(OH)D 3 [12] [13] [14] . The consideration that effects of 25(OH)D 3 occur through conversion to 1,25(OH) 2 D 3 is supported by several in vitro blocking studies. In CYP27B1-silenced HOS cells, a human osteoblast cell line, it has been shown that exposure to 25(OH)D 3 leads to a decline of osteonectin and CYP24 mRNA expression compared to control cells [21] . In human marrow stromal cells differentiated to osteoblasts, CYP27B1 is reported to be necessary for the antiproliferative and prodifferentiation effects of 25(OH)D 3 [20] . Furthermore, in SV-HFO osteoblasts, ketoconazole almost complete blocked the effects of 25(OH)D 3 on osteocalcin mRNA levels [12] .
In our study, CYP27B1-silencing resulted in a decline of 1,25(OH) 2 D 3 synthesis by primary osteoblasts. Despite this reduction, no significant differences in mRNA levels of differentiation markers were seen in CYP27B1-silenced cells compared to control cells after treatment with 25(OH)D 3 . It is likely that Levels of 24R,25(OH) 2 D 3 were present in control and silenced cultures. Moreover, we showed that osteoblast cultures exposed to 24R,25(OH) 2 D 3 had increased mRNA levels of ALP, osteocalcin and osteopontin. These results indicate a role for 24R,25(OH) 2 D 3 in osteoblast differentiation. This is in line with previous research in the human osteoblast cell line SV-HFO in which 24R,25(OH) 2 D 3 stimulated ALP activity and osteocalcin secretion by binding to the VDR [17] . Our results are also supported by a study in human mesenchymal stem cells, in which 24R,25(OH) 2 D 3 enhances the osteoblastic differentiation by increasing ALP activity, osteocalcin mRNA levels and calcium mineralization of matrix [22] . In addition, our results are supported by a study in primary human osteoblasts that found increased osteocalcin production after 24R,25(OH) 2 [17] .
In addition to the actions of 24R,25(OH) 2 D 3 on mRNA levels of differentiation genes, 24R,25(OH) 2 D 3 was also able to markedly enhance mRNA levels of CYP24. This may result in a higher production of 24R,25(OH) 2 D 3 which suggests that 24R,25(OH) 2 D 3 has the ability to regulate its own synthesis in a positive way (positive feedback). This is not in line with research performed in human mesenchymal stem cells differentiated to osteoblasts [22] . These osteoblasts decrease their CYP24 mRNA levels in response to 24R,25(OH) 2 D 3 (at a concentration of 10 nmol/L) [22] . Added concentrations of 24R,25(OH) 2 Results were analysed using Friedman test followed by Dunn's post hoc test (*p,0.05, **p,0.01, ***p,0.001). doi:10.1371/journal.pone.0110283.g008 [24] . In our study, 24R,25(OH) 2 [22] .
The metabolite 25(OH)D 3 itself may also be capable to activate the VDR and to subsequently affect mRNA levels of differentiation genes. This is supported by the in vivo study of Rowling et al [25] that supraphysiological levels of 25(OH)D 3 can affect calcium and bone metabolism in the absence of its hydroxylation to 1,25(OH) 2 D 3 . In this study CYP27B1 knock out mice were fed a diet high in cholecalciferol which prevented hypocalcemia and almost rescued skeletal growth [25] . Several in vitro studies also support the hypothesis that 25(OH)D 3 has direct effects on cells. Curtis [22] showed that 25(OH)D 3 stimulates osteoblast mineralization in the presence of the cytochrome P450 inhibitor ketoconazole. Lou et al [26] [24] reported that the binding affinity for 25(OH)D 3 to the VDR is 50 times less than 1,25(OH) 2 D 3 .
In bone tissue, 25(OH)D 3 metabolism may be beneficial since it is thought that locally synthesized 1,25(OH) 2 D 3 supports osteoblast differentiation and matrix mineralization [12, 13, 27] . Serum 25(OH)D 3 levels serve as substrate for local 25(OH)D 3 metabolism and an adequate vitamin D status may therefore be essential [28] . In addition, low 25(OH)D 3 serum levels in the range of deficiency may be a limiting factor for the synthesis of 1,25(OH) 2 D 3 [29] and 24R,25(OH) 2 D 3 , and may result in reduced osteoblast differentiation and thereby a reduction of bone strength.
A limitation of this study is that complete blocking of the 1,25(OH) 2 D 3 synthesis was not achieved in the RNA-silencing experiments. Therefore the question whether 25(OH)D 3 itself is able to affect osteoblast function, can not be answered. Additional research is needed to achieve completely blocking of 1,25(OH) 2 
